Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company was founded in 2005 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNAT
CUSIPN/A
Phone858-376-2600
Debt
Debt-to-Equity Ratio0.68
Current Ratio2.35
Quick Ratio2.35
Price-To-Earnings
Trailing P/E Ratio-7.20
Forward P/E Ratio-6.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.38 million
Price / Sales3.74
Cash FlowN/A
Price / CashN/A
Book Value$0.93 per share
Price / Book4.72
Profitability
EPS (Most Recent Fiscal Year)($0.61)
Net Income$-17,390,000.00
Net Margins-48.46%
Return on Equity-69.68%
Return on Assets-22.71%
Miscellaneous
Employees35
Outstanding Shares30,150,000
Market Cap$143.79 million
Conatus Pharmaceuticals (NASDAQ:CNAT) Frequently Asked Questions
What is Conatus Pharmaceuticals' stock symbol?
Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."
How were Conatus Pharmaceuticals' earnings last quarter?
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) posted its quarterly earnings results on Friday, August, 3rd. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.05. The biotechnology company earned $8.77 million during the quarter, compared to analysts' expectations of $9.06 million. Conatus Pharmaceuticals had a negative return on equity of 69.68% and a negative net margin of 48.46%. View Conatus Pharmaceuticals' Earnings History.
When is Conatus Pharmaceuticals' next earnings date?
What price target have analysts set for CNAT?
4 Wall Street analysts have issued 12 month price targets for Conatus Pharmaceuticals' stock. Their predictions range from $4.30 to $20.00. On average, they expect Conatus Pharmaceuticals' stock price to reach $11.7980 in the next year. This suggests a possible upside of 162.2% from the stock's current price. View Analyst Price Targets for Conatus Pharmaceuticals.
What is the consensus analysts' recommendation for Conatus Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Conatus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Conatus Pharmaceuticals.
Are investors shorting Conatus Pharmaceuticals?
Conatus Pharmaceuticals saw a increase in short interest in the month of September. As of September 28th, there was short interest totalling 2,480,490 shares, an increase of 55.9% from the September 14th total of 1,591,036 shares. Based on an average daily trading volume, of 1,372,693 shares, the short-interest ratio is currently 1.8 days. Currently, 9.4% of the shares of the stock are short sold. View Conatus Pharmaceuticals' Current Options Chain.
Who are some of Conatus Pharmaceuticals' key competitors?
Some companies that are related to Conatus Pharmaceuticals include ChemoCentryx (CCXI), Basilea Pharmaceutica (BPMUF), Dermira (DERM), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), TIGENIX/S (TIG), Collegium Pharmaceutical (COLL), Principia Biopharma (PRNB), Ra Pharmaceuticals (RARX), Arcus Biosciences (RCUS), Prothena (PRTA), Five Prime Therapeutics (FPRX), Arvinas (ARVN), Aduro BioTech (ADRO) and Rigel Pharmaceuticals (RIGL).
Who are Conatus Pharmaceuticals' key executives?
Conatus Pharmaceuticals' management team includes the folowing people:
- Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 66)
- Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 50)
- Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 63)
- Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 60)
- Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications
How do I buy shares of Conatus Pharmaceuticals?
Shares of CNAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Conatus Pharmaceuticals' stock price today?
One share of CNAT stock can currently be purchased for approximately $4.50.
How big of a company is Conatus Pharmaceuticals?
Conatus Pharmaceuticals has a market capitalization of $143.79 million and generates $35.38 million in revenue each year. The biotechnology company earns $-17,390,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Conatus Pharmaceuticals employs 35 workers across the globe.
What is Conatus Pharmaceuticals' official website?
How can I contact Conatus Pharmaceuticals?
Conatus Pharmaceuticals' mailing address is 16745 WEST BERNARDO DRIVE Suite 200, San Diego CA, 92127. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected]
MarketBeat Community Rating for Conatus Pharmaceuticals (NASDAQ CNAT)
MarketBeat's community ratings are surveys of what our community members think about Conatus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
